logo

For the Inventor, By the Inventor

Saffron Walden, United Kingdom

Graeme Irvine Stevenson

USPTO Granted Patents = 12

Average Co-Inventor Count = 3.4

ph-index = 7

Forward Citations = 210(Granted Patents)


Location History:

  • Staffron Walden, GB (1996)
  • Saffon Walden, GB (1997)
  • Saffron Waldøn, GB (2006)
  • Saffron Walden, GB (1997 - 2008)

Company Filing History:

goldMedal12 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal1 out of 76 
 
Merck Frosst Canada & Co.
 patents
where one patent can have more than one assignee

Years Active: 1996-2008

Loading Chart...
12 patents (USPTO):Explore Patents
1. 7365196 - Sulphonamido-substituted bridged bicycloalkyl derivatives (2008-04-29),
2. 7049296 - Gamma-secretase inhibitors (2006-05-23),
3. 6984626 - Gamma-secretase inhibitors (2006-01-10),
4. 6486153 - Phenylindole derivatives as 5-HT2A receptor ligands (2002-11-26),
5. 5985896 - Piperidine and morpholine derivatives and their use as therapeutic agents (1999-11-16),
6. 5885999 - Serine derivatives and their use as therapeutic agents (1999-03-23),
7. 5830892 - Piperidine and morphonline derivatives and their use as therapeutic (1998-11-03),
8. 5760018 - Gem-disubstituted azacyclic tachykinin antagonists (1998-06-02),
9. 5663352 - 4-phenyl-4-phenylpropyl(enyl)-piperidines as tachykinin antagonists (1997-09-02),
10. 5661162 - 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin (1997-08-26),
11. 5620989 - 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits (1997-04-15),
12. 5563161 - Alcohols and ethers with aromatic substituents as tachykinin-antagonists (1996-10-08),

Title: Graeme Irvine Stevenson: Innovator in Alzheimer's Disease Treatment

Introduction

Graeme Irvine Stevenson is a notable inventor based in Saffron Walden, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating Alzheimer's disease. With a total of 12 patents to his name, Stevenson has established himself as a key figure in medical innovation.

Latest Patents

Stevenson's latest patents include groundbreaking work on sulphonamido-substituted bridged bicycloalkyl derivatives. This class of compounds is designed to inhibit gamma-secretase, making them potentially useful in the treatment and prevention of Alzheimer's disease. Another significant patent involves urea derivatives that also act as inhibitors of gamma-secretase, further contributing to the fight against this debilitating condition.

Career Highlights

Throughout his career, Stevenson has worked with prominent companies such as Merck Sharp & Dohme Corp. and Merck Frosst Canada & Co. His experience in these organizations has allowed him to collaborate with leading experts in the field and to refine his innovative ideas into practical applications.

Collaborations

Stevenson has collaborated with notable colleagues, including Angus Murray MacLeod and Jason Matthew Elliott. These partnerships have played a crucial role in advancing his research and patent developments.

Conclusion

Graeme Irvine Stevenson is a distinguished inventor whose work has the potential to significantly impact the treatment of Alzheimer's disease. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…